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PathogenesisInﬂuenza A virus particles assemble and bud from plasma membrane domains enriched with the viral
glycoproteins but only a small fraction of the total M2 protein is incorporated into virus particles when
compared to the other viral glycoproteins. A membrane proximal cholesterol recognition/interaction amino
acid consensus (CRAC) motif was previously identiﬁed in M2 and suggested to play a role in protein function.
We investigated the importance of the CRAC motif on virus replication by generating recombinant proteins
and viruses containing amino acid substitutions in this motif. Alteration or completion of the M2 CRAC motif
in two different virus strains caused no changes in virus replication in vitro. Viruses lacking an M2 CRAC
motif had decreased morbidity and mortality in the mouse model of infection, suggesting that this motif is a
virulence determinant which may facilitate virus replication in vivo but is not required for basic virus
replication in tissue culture.t), wwu20@jhmi.edu
jhsph.edu (A. Pekosz).
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Inﬂuenza A virus remains a major public health burden and
potential pandemic threat even with widespread annual vaccination
and the availability of antivirals. TheM2 protein is required for several
steps in the viral life cycle (reviewed in Pinto and Lamb, 2007).
Following hemagglutinin (HA)-mediated virus-cell membrane fusion,
the ion-channel activity of M2 is activated in acidiﬁed endosomes. M2
translocates protons into the core of the virus particle whichmediates
the release of viral ribonucleoprotein (vRNP) complexes from their
association with matrix (M1) protein and viral membranes. The
vRNPs are tranported to the nucleus where viral transcription and
genome replication occurs. The ion-channel activity of M2 also raises
the pH of the Golgi compartment, thereby preventing the low pH
induced conformational changes in HA proteins which are processed
to their fusion-competent forms by intracellular proteases. Virus
particle assembly occurs at the plasma membrane and the cytoplas-
mic tail of M2 is required for efﬁcient incorporation of vRNP into
infectious virus particles (McCown and Pekosz, 2005, 2006).
Inﬂuenza A virus particles assemble and bud from plasma
membrane domains enriched with the viral glycoproteins, HA and
neuraminidase (NA). These domains may also reﬂect lipid rafts (Leserand Lamb, 2005; Scheiffele et al., 1999; Zhang et al., 2000). The
cytoplasmic tails of HA and NA bind and recruit M1 tomembranes (Ali
et al., 2000). Even though M2 is not found at these sites of
glycoprotein enrichment, a small amount of M2 is incorporated into
virus particles (Leser and Lamb, 2005; Zhang et al., 2000). Addition-
ally, the amount of M2 incorporation can be increased if the
glycoproteins are targeted away from lipid microdomains by the
deletion of their cytoplasmic tails (Chen et al., 2005).
Several mechanisms have been hypothesized to contribute to M2
virion incorporation, including random incorporation and incorpora-
tion via interaction with cholesterol (Schroeder et al., 2005). A
membrane proximal cholesterol recognition/interaction amino acid
consensus (CRAC) motif has been identiﬁed in the peripheral-type
benzodiazepine receptor and other proteins known to bind choles-
terol (Li and Papadopoulos, 1998), including caveolin-1 (Epand et al.,
2005) and human immunodeﬁciency virus (HIV) gp41 (Greenwood et
al., 2008; Vincent et al., 2002; Vishwanathan et al., 2008). The CRAC
motif in gp41 is adjacent to a transmembrane helix and has been
shown to bind cholesteryl-hemisuccinate agarose (Vincent et al.,
2002). Mutation of the motif decreased cholesterol binding but also
altered fusogenic activity when introduced into HIV (Epand et al.,
2006; Vishwanathan et al., 2008). Schroeder et al. (2005) identiﬁed a
putative CRAC motif in M2 and determined that M2 protein puriﬁed
from a baculovirus expression system binds cholesterol. A second
CRAC motif immediately downstream of the ﬁrst one is present in a
limited number of inﬂuenza virus strains. They suggest that
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microdomains, thereby facilitating M2 incorporation into virions.
Because M2 is required during several distinct steps in the virus life
cycle, we investigated the importance of the CRAC motif on virus
replication by generating recombinant proteins and viruses contain-
ing alterations in this motif.
Results
Oligomerization and expression of mutant M2 proteins in stable cell lines
Inﬂuenza A/WSN/33 (rWSN) encodes an M2 protein with a
consensus (L/V-X(1-5)-Y-X(1-5)-R/K ) CRAC motif (Jamin et al., 2005;
Lacapere and Papadopoulos, 2003; Li and Papadopoulos, 1998; Li et al.,
2001; reviewed in (Epand, 2006) while A/Udorn/72 (rUd) encodes a
protein with an R at position 54 which disrupts the consensus (Fig. 1).
These inﬂuenza virus strains do not possess a second putative CRAC
domain (Schroeder et al., 2005). Mutations were made in rWSNM2 to
alter the CRAC motif by either mutating residue 54 from arginine to
phenylalanine (rWSN M2 R54F), the amino acid found in the rUd M2
protein, or changing all of the critical CRAC motif residues to alanine
(rWSN M2 delCRAC) in order to eliminate the consensus sequence.
Additionally, the CRAC motif in rUd M2 was completed by mutating
residue 54 from phenylalanine to arginine (rUd M2 F54R). The WSN
M2 proteins also contain an asparagine to serine mutation at residue
31 which conveys amantadine sensitivity (Hay et al., 1985; Takeda et
al., 2002) so that the potentially toxic effects of ion channel activity
could be inhibited during routine cell culture.
Stably transfected MDCK cell lines were generated which
constitutively express the wild-type or mutant M2 proteins. Mutation
of the CRAC motif does not affect M2 protein oligomerization as
determined by non-reducing SDS–PAGE and Western blotting
(Figs. 2A and D). To determine if the mutant M2 proteins were
expressed at the cell surface, ﬂow cytometry was performed on live
cells using an antibody which recognizes the extracellular domain of
M2. Greater than 90% of the cells express M2 at the cell surface
(Figs. 2B and E). The total amount of mutant M2 expressed in the
stable cell lines was comparable to a control cell line expressing wild-
typeM2 protein (Fig. 2A and D) as was the amount of M2 expressed at
the cell surface (data not shown).
M2 proteins with altered CRAC motifs are able to complement
M2-deﬁcient viruses
The M2 protein plays several roles in the virus life cycle and
altering any of these functions can drastically reduce virus replication
and ﬁtness (Iwatsuki-Horimoto et al., 2006; McCown and Pekosz,Fig. 1. Sequence alignment of M2 residues 46–56. The amino acids that deﬁne the CRAC
motif are in bold and substitutions that disrupt or complete the consensus are
indicated. An asterisk indicates no change in sequence. The rWSNM2 R54F mutant still
contains a potential CRAC consensus sequence due to the presence of another basic
amino acid at position 56.2005, 2006; Takeda et al., 2002). The ability of stably expressed M2 to
complement M2-deﬁcient viruses has been previously used to study
mutations in M2 which may prevent the rescue of recombinant
viruses (Chen et al., 2008; McCown and Pekosz, 2005, 2006; Thomas
et al., 1998). To determine if M2 proteins with mutations in the CRAC
motif are able to complement M2-deﬁcient viruses, stable cell lines
expressing M2 were infected with viruses which contain a stop codon
in their M2 gene (M2Stop viruses). Neither alteration of the CRAC
motif (Fig. 2C) nor completion of the CRACmotif (Fig. 2F) resulted in a
statistically signiﬁcant change in the production of infectious virus
when compared to wt M2, indicating all the mutated M2 proteins are
fully functional in this assay.
Alteration of M2 CRAC motif does not affect the replication of
recombinant inﬂuenza A viruses in tissue culture
In order to conﬁrm that mutation of the CRAC motif in the M2
protein does not affect virus replication, recombinant viruses were
generated which encode M2 proteins with mutations in the CRAC
motif (Fig. 1). Infection of MDCK cells with these viruses results in a
similar level of cell surface M2 as determined by ﬂow cytometry
(Figs. 3A and D). Multistep growth curves in MDCK (Figs. 3B and E)
and the human lung adenocarcinoma, CaLu-3 cells (Figs. 3C and F),
result in no statistically signiﬁcant changes in either replication
kinetics or peak infectious virus titers, indicating the recombinant
viruses with altered M2 CRAC motifs maintain the ability to replicate
in these cell lines.
Many primary and some laboratory-adapted inﬂuenza A virus
strains produce ﬁlamentous particles, including rUd, while most
laboratory-adapted inﬂuenza A virus strains, such as rWSN, produce
spherical particles (Mosley and Wyckoff, 1946; Roberts and Com-
pans, 1998; Roberts et al., 1998). In order to determine if completion
of the CRAC motif in UdM2 affects the ability of recombinant virus to
produce ﬁlamentous particles, confocal microscopy was performed
to compare the number of infected cells which produce ﬁlaments.
Filaments formed by both rUdM2 F54R andwild-typewere similar in
appearance (Figs. 4A and B), and the number of infected cells
showing ﬁlaments was not signiﬁcantly different (Fig. 4C). Addi-
tionally, like wild-type rWSN, rWSNM2 R54F and rWSNM2 delCRAC
failed to formed ﬁlaments on the surface of infected cells (data not
shown). In order to determine if the ﬁlamentous virus particles were
similar in size and structure, transmission electronmicrographswere
taken of infected MDCK cells. The rUd virus encoding M2 F54R was
able to produce ﬁlamentous particles like wild-type virus (Figs. 4D
and E). Together, these data indicate that completion of the CRAC
motif does not alter the ability of inﬂuenza virus to produce
ﬁlamentous virus particles.
Virion protein composition of recombinant viruses encoding M2 CRAC
mutants
In order to investigate the requirement of the CRAC motif for
incorporation of viral proteins into virions, virus particles were
collected and concentrated through a 20% sucrose cushion by
ultracentrifugation. Virus pellets were resuspended and the amount
of incorporated viral proteins was determined by Western blot
(Figs. 5A and B). Relative amounts of full-lengthM2 and total M2were
quantiﬁed from replicate experiments. Total M2 incorporated into
either CRAC altered or CRAC completed recombinant viruses was not
statistically different from wild-type (Figs. 5C and D). There was a
statistically signiﬁcant decrease in the amount of full-length M2
protein incorporated into rWSN M2 R54F virions. The truncated form
of M2 is thought to be generated via cleavage by caspases at the C-
terminus of M2 but this cleavage does not appear to affect viral
replication (Zhirnov et al., 2002; Zhirnov and Syrtzev, 2009).
Additionally, HA, NP, and M1 were incorporated into virus particles
Fig. 2. Expression and function ofM2 proteinswithmodiﬁed CRACmotifs. (A andD)MDCK cells expressing the indicatedM2 proteinswere analyzed byWestern blotting to detect
disulﬁde linked oligomeric forms of theM2 protein. Monomers, dimers, and trimers are indicated and some higher order oligomers can be detected. (B and E) The number of cells
expressing M2 at the cell surface was quantiﬁed by ﬂow cytometry from the indicated stably transfected MDCK cell lines. (C and F) The ability of the indicated stably transfected
MDCK cells to complement infection with a recombinant inﬂuenza virus that does not encode the full-length M2 protein was assessed by infecting the cells with the indicated
recombinant virus and quantifying infectious virus production at various hours post infection (hpi). The average and standard error of the mean are graphed. The standard error
bars are smaller than the size of the individual points. The limit of detection is marked by a horizontal dotted line. Proteins or recombinant viruses based on the rWSN (A–C) and
rUd virus strains (D–F) were used.
532 S.M. Stewart et al. / Virology 405 (2010) 530–538at levels indistinguishable from wild-type M2 when the M2 CRAC
motif was altered or completed (Figs. 5A and B; data not shown).
Decreased morbidity and mortality in mice infected with recombinant
viruses expressing M2 CRAC mutants
SomeM2mutations have been shown to have no effect in vitro but
display decreased in vivo pathogenesis (Grantham et al., 2009;
Watanabe et al., 2008; Wu and Pekosz, 2008). In order to determine
if mutation of the M2 CRAC motif affects in vivo pathogenesis, mice
were infected with rWSN viruses expressing the wild-type M2, M2
R54F, or M2 delCRAC. When intranasally inoculated with 103 TCID50,
mice infected with all viruses displayed similar survival (Fig. 6A).
When mice were infected with 105 TCID50 of virus, rWSN caused
signiﬁcantly more mortality compared to rWSN M2 R54F and rWSN
M2 delCRAC (Fig. 6B). The median time to death for rWSN (7 days)
and rWSN M2 R54F (11 days) differed as well. Change in body mass
induced by infection with 103 TCID50 of either rWSN or rWSN M2
R54F was more signiﬁcant than that induced by rWSN M2 delCRAC
(Fig. 6C). Mice infected 105 TCID50 of the viruses did not display
signiﬁcant differences in loss of body mass over the ﬁrst 6 days of
infection, despite the decreased mortality of mice infected with the
CRAC altered recombinant viruses (Fig. 6D). Infection of micewith 105
TCID50 of rUd M2F54R did not result in a signiﬁcant increase in virus
replication or morbidity when compared to rUd, suggesting that
restoration of the complete CRAC domain did not enhance in vivoreplication of rUd (data not shown). These data indicate that
elimination of the M2 CRAC motif leads to a modest attenuation of
virus virulence in the mouse model of infection despite no obvious
defects in in vitro virus replication.
Alteration of the M2 CRAC motif does not affect replication of recombinant
inﬂuenza A viruses in mTEC cultures
Given the discrepancy between the ability of the recombinant
viruses to replicate in tissue culture cells and their attenuation in the
mouse model of infection, we investigated whether virus infection of
mTEC cultures would better reﬂect the in vivo virus phenotypes. These
primary cell cultures are differentiated into cell types normally found
in the mouse trachea and therefore represent a faithful tissue culture
surrogate for virus infection of the airways (Ibricevic et al., 2006b;
Newby et al., 2007; Pekosz et al., 2009). There was no statistically
signiﬁcant difference in the replication of the mutant viruses in mTEC
cultures as compared to the corresponding wild-type virus (Fig. 7),
suggesting that replication in mTEC cultures was not compromised by
altering the CRAC motif.
Discussion
This study sought to investigate the role of the CRACmotif found in
the M2 protein of two inﬂuenza A virus strains. The R54F mutation in
the WSNM2 protein was made to mimic the amino acid found at that
Fig. 3. The effects of altering the CRAC motif on replication in tissue culture. (A and D) MDCK cells were infected with the indicated viruses at an MOI of ~3 and the cell surface
expression of M2 protein was measured by ﬂow cytometry at 15h post infection (hpi). The relative expression of M2 represents the mean channel ﬂuorescence of the indicated
infected cells divided by themean channel ﬂuorescence of the wild-type infected cells. MDCK (B and E) or CaLu-3 (C and F) cells were infected at anMOI of ~0.001 with the indicated
recombinant viruses. At the indicated hpi, infected cell supernatants were harvested and the number of infectious virus particles determined by TCID50 assay. Data points represent
the average and standard error of the mean. The horizontal dotted line is the limit of detection.
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putative consensus CRAC sequence because it has another basic amino
acid at residue 56. This could explain why this virus has an
intermediate change in virulence when compared to rWSN and
rWSN delCRAC. Mutation of WSN M2 to either R54F or delCRAC leads
to no changes in virus replication in vitro. Likewise, completion of the
CRACmotif in the UdM2 protein also has no effect on virus replication
in MDCK cells, CaLu-3 cells or in mTEC cultures. Together, this
suggests that the CRAC motif is not required for in vitro replication of
inﬂuenza A virus.
Even though the CRAC motif is not essential for in vitro virus
replication, mutation of the motif resulted in decreased morbidity
andmortality whenmice were infectedwith a virus lacking the CRAC
motif. The decreased pathogenesis of mutants may suggest that the
CRAC motif of the M2 protein may be a virulence determinant in that
it is not required for in vitro virus replication but is critical for efﬁcient
virus infection in animal models. It is also possible that presence of a
complete CRAC motif in M2 protein contributes to virus infection of
other cell types such as alveolar epithelial cells or macrophages.
Rossman et al. (2010) recently demonstrated that amino acids
outside of the CRAC domain contribute to the cholesterol binding of
M2 andmutation of these amino acid sequences leads to decreased in
vitro replication. The M2 protein only showed cholesterol binding
activity in the context of a virus infection and changes at multiple
amino acids that line the hydrophobic face of a membrane proximal
alpha helix of the protein were demonstrated to be critical for in vitro
virus replication. This suggests that the CRAC motif in and of itself is
not required for inﬂuenza virus replication in vitro, a fact supported
by our data.
The cytoplasmic tail of M2 has been implicated in the stabiliza-
tion of the open state of the M2 ion channel (Schnell and Chou, 2008;
Tobler et al., 1999), virion incorporation of M1 and vRNP (Iwatsuki-Horimoto et al., 2006; McCown and Pekosz, 2005, 2006), virus
morphology (Iwatsuki-Horimoto et al., 2006), and virus infectivity
(Chen et al., 2008; Iwatsuki-Horimoto et al., 2006; McCown and
Pekosz, 2005, 2006; Takeda et al., 2002). Although the transmem-
brane domain of M2 has been studied by NMR and crystallography,
the structure of the cytoplasmic domain is less well understood
(Schnell and Chou, 2008; Stouffer et al., 2008). The structure of
residues 45–60 of the M2 cytoplasmic tail has been determined by
NMR in concert with the transmembrane domain (Schnell and Chou,
2008), but the structure of the entire cytoplasmic tail has yet to be
determined. Residues 47–50 form a short, ﬂexible loop linking the
transmembrane domain to a C-terminal amphipathic helix (residues
51–59) that forms a stable “base” important for holding the
tetramers together during the conformational changes associated
with ion-channel activation. The CRAC domain and a site for
palmitoylation (Ser 50) fall into these regions and it has been
speculated that these modiﬁcations may stabilize the interaction of
the M2 cytoplasmic tail with lipid membranes (Schnell and Chou,
2008). Elimination of the CRAC motif or the M2 palmitoylation site
(Grantham et al., 2009) does not alter virus replication in vitro but
does yield viruses that are attenuated in the mouse model of
infection. These data argue against a critical role for these two
sequences in virus replication, though both sequences are essential
for maintaining virus virulence in vivo. While these sequences may
be dispensable for virus replication, this does not imply that this
region of the M2 protein is not important for M2 function either as a
structural motif, or through properties as yet undeﬁned.
The CRACmotif in the M2 protein is not required for incorporation
of M2 into virions nor does it affect the incorporation of other viral
proteins. Alternate methods mediating the incorporation of M2 into
virions must therefore exist. One study suggests that the ectodomain
of M2 can drive a foreign protein to be incorporated into inﬂuenza A
Fig. 5. The effects of altering the CRACmotif on incorporation of structural proteins. MDCK
cells were infected with the indicated viruses at an MOI of 5. At 15hpi, virus particles were
collected andconcentrated through a20% sucrose cushion at 118,000 g for 1 h.Virus pellets
were resuspended and incorporation of viral proteins was determined by Western blot
with antibodies which detect the structural proteins HA, NP, M1, and M2. (A and B)
RepresentativeWesternblots showing incorporationof viralproteins intovirions. (CandD)
Quantiﬁcation of full-lengthM2 and total M2 fromWestern blot analysis of replicate virion
incorporation assays. A large amount of pelleted virionswas loaded onto the SDS–PAGE gel
in order to detect the relatively low amounts of incorporated M2 protein. Relative
expression was determined by the negative log of M1 normalized data. Recombinant
viruses based on the rWSN (A and C) or rUd virus strains (B and D) were used. *pb0.05.
Fig. 4. Theeffects of completing theCRACmotif on formation ofﬁlamentous virus particles.
MDCK cellswere infectedwith 500,000 TCID50 (~0.9MOI). At 15 hpi, immunoﬂuorescence
staining was performed for HA and visualized by confocal microscopy. Confocal Z-sections
(takenwith a 100× objective) of rUd (A) or rUdM2 F54R (B)-infected cells were ﬂattened
and show viral ﬁlaments for both viruses. The percentage of infected cells showing
ﬁlaments was determined from 10 to 20 images taken with a 20× objective on an
epiﬂuorescencemicroscope (C). One representative experiment is shown. For TEM, MDCK
cells were infected at an MOI of ~5. Samples were processed for transmission electron
microscopyat 10 hpi. Cellswere infectedwith rUd (D)or rUdM2 F54R (E). Arrows indicate
microvilli, solid arrowheads indicate ﬁlamentous virus particles, and empty arrowheads
mark either spherical virus particles or cross-sections of ﬁlamentous virus particles.
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Fig. 6. Mortality and morbidity of mice infected with recombinant inﬂuenza A/WSN/33 viruses encoding M2 proteins with altered CRAC motifs. Mice were administered an
intranasal dose of 103 (A and C) or 105 (B and D) TCID50 of the indicated viruses and monitored for 14 days post infection (dpi). (A and B) Mortality and (C and D) morbidity
associated with infection, as judged by loss of starting weight. Data points indicate the average and standard deviation. Signiﬁcant differences in B are between the CRAC altered
viruses and rWSN while in C the differences are between rWSN M2 delCRAC and the other two viruses. *pb0.05 and **pb0.01.
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between the M2 ectodomain and the ectodomains of the other viral
glycoproteins. The mechanism by which a limited amount of M2 is
incorporated into virus particles despite the high amounts of M2located in the plasma membrane but not in the same membrane
microdomains as the glycoproteins remains to be determined.
Materials and methods
Plasmids
The plasmid pCAGGS (Niwa et al., 1991)was used forM2 expression
in mammalian cells. A plasmid expressing the M2 cDNA from inﬂuenza
A/Udorn/72 (Ud M2) has been described previously (McCown and
Pekosz, 2005). The M2 coding region from inﬂuenza A/WSN/33
(GenBank accession number ABF21317) was ampliﬁed by RT-PCR and
cloned as described previously forM2Ud (McCown et al., 2003). AWSN
M2 cDNA encoding a protein sensitive to the antiviral drug amantadine
was constructed by changing the amino acid at position 31 from
arginine to serine (N31S) (Takeda et al., 2002). All M2 mutations were
introduced into the expression plasmids by overlap extension PCR and
the sequences of the mutated plasmids were conﬁrmed. Primer
sequences are available upon request.
ThepBABEplasmid,which expresses puromycinN-acetyltransferase,
was used to generate stable cell lines expressingmutant M2 proteins as
previously described (Morgenstern and Land, 1990).
In order to generate recombinant inﬂuenza viruses expressing M2
proteins with altered CRAC motifs, mutations were introduced intoFig. 7. The effects of altering the CRAC motif on replication in mouse tracheal epithelial
cell (mTEC) cultures. mTEC cultures were infected with 3300 TCID50 (~0.01 MOI) of the
indicated recombinant viruses in the rWSN (A) or rUdorn (B) genetic backgrounds. At
the indicated hpi, infected cell supernatants were harvested and the number of
infectious virus particles determined by TCID50 assay in MDCK cells. Data points
represent the average and standard error of the mean. The horizontal dotted line is the
limit of detection.
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(Stratagene). The sequence of the entire M segment of the resulting
plasmid was conﬁrmed.
Cells
Madin–Darby canine kidney (MDCK) cells, human lung adenocar-
cinoma (CaLu-3) cells (ATCC HTB-55), and human embryonic kidney
(293 T) cells (Takeda et al., 2002) were cultured in Dulbecco's
modiﬁed Eaglemedium (DMEM) supplementedwith 10% fetal bovine
serum (FBS, Atlanta Biologicals), 100 U/mL penicillin (Invitrogen),
100 μg/mL streptomycin (Invitrogen), 1 mM sodium pyruvate
(Sigma), and 2 mM GlutaMAX (Invitrogen). Cells were maintained
at 37 °C in a humidiﬁed 5% CO2 environment.
Generation of stable cell lines
MDCK cells stably expressing M2 proteins were generated as
described previously (McCown and Pekosz, 2005). Brieﬂy, MDCK cells
were cotransfected in suspension with 1 μg pCAGGS M2 expression
plasmid and 0.5 μg pBABE puromycin expression plasmid using 9 μL of
Lipofectamine 2000 (Invitrogen) as per the manufacturer's protocol.
Cells were plated into 6-well plates, selected using 7.5 μg/mL
puromycin dihydrochloride (Sigma), and single colonies were
isolated and expanded. Expression of M2 was conﬁrmed by indirect
immunoﬂuorescence staining of surface M2 using monoclonal
antibody (MAb) 14C2. M2 expressing cells were maintained with
5 μM amantadine hydrochloride (Sigma).
Viruses
The viruses used in this study were rWSN and rUd (recombinant
versions of A/WSN/33 and A/Udorn/72, respectively). Viruses were
generated using a 12-plasmid rescue system described previously
(McCown and Pekosz, 2005, 2006; Neumann et al., 1999; Takeda et al.,
2002). The sequence of the entire coding region of the M segment of
all rescued viruses was conﬁrmed. There were no discernable
differences in plaque size or morphology between any of the
recombinant viruses (data not shown).
Virus growth curves were performed at a multiplicity of
infection (MOI) of ~0.001. For complementation assays, MDCK
cells expressing mutant M2 proteins were infected with recombi-
nant viruses that were functionally deleted for the expression of M2
(M2stop viruses) as described previously (McCown and Pekosz,
2006). For recombinant viruses, mutant M2-expressing viruses
were used to infect MDCK or CaLu-3 cells. Cells were infected by
twice washing conﬂuent 6-well plates of MDCKs with phosphate-
buffered saline (PBS, Invitrogen) then infecting with the indicated
viruses in 500 μL infectious media (DMEM supplemented with 5%
bovine serum albumin (BSA, Calbiochem), 100 U/mL penicillin,
100 μg/mL streptomycin, 2 mM GlutaMAX, and 4 μg/mL N-acetyl
trypsin (NAT, Sigma)) at room temperature with rocking for 1 h.
Cells were then washed twice with PBS and incubated with 500 μL
infectious media. Media were removed and replaced with fresh
media at the indicated time points. Infectious virus titers were
quantiﬁed by determining the 50% tissue culture infectious dose
(TCID50) on MDCK cells (for M2-expressing viruses) or MDCK cells
expressing WSN M2 N31S (for M2Stop viruses). Media lacking
trypsin was used for infection of CaLu-3 cells. Standard error of the
mean is graphed from infections done in duplicate or triplicate. The
experiments were repeated at least twice and one representative
example is graphed.
For microscopy, MDCK cells were grown to conﬂuency on tissue
culture treated glass coverslips and media changed every 2 days. Four
days after conﬂuence, cells werewashed twicewith PBS, infectedwith
500,000 TCID50 (~0.9MOI) of the indicated virus in 500 μLmedium for1 h at room temperature. Cells were then washed, the media were
replaced and the cells incubated at 37 °C for 15h.
Virus puriﬁcation
Virus particles were isolated from the supernatants of MDCK cells
infected at an MOI of 5 for 15 h. Cell debris was removed by
centrifugation at 1900×g for 10 min at 4 °C. Virus particles were then
concentrated through a 20% sucrose cushion with centrifugation at
118,000×g in a TH641 rotor (Sorval) for 1 h at 4 °C. Virus pellets were
resuspended in 100 μL PBS and mixed 1:1 in 2× SDS–PAGE sample
buffer.
SDS–PAGE and Western blotting
MDCK cells were lysed in 1% SDS (Fisher Scientiﬁc) in PBS and
mixed 1:1 in 2× SDS–PAGE sample buffer. Polypeptides were resolved
on 17.5% polyacrylamide gel with 4 M urea and transferred to
polyvinylidene diﬂuoride membranes (PVDF, Millipore). Membranes
were blocked with PBS containing 0.3% Tween-20 (Sigma) and 5% dry
milk, incubated 1 h RT with primary antibody, washed three times
with PBS with 0.3% Tween-20, incubated 1 h RT with secondary
antibody, and washed four times with PBS containing 0.3% Tween-20.
The primary antibodies used were mouse α-M2 14C2 MAb (1:1000
dilution) (Zebedee and Lamb, 1988), mouse α-M1 HB-64 MAb (1:100
dilution) (McCown and Pekosz, 2005; Yewdell et al., 1981), mouse α-
NP HB-65 MAb (1:100 dilution) (McCown and Pekosz, 2005; Yewdell
et al., 1981), goatα-A/Udorn/72 serum (1:500 dilution) (Zhang et al.,
2000), or goat α-HA0 A/PR/8/34 (1:500 dilution, V-314-511-157;
National Institute of Allergy and Infectious Diseases). Secondary
antibodies were goatα-mouse immunoglobulin G (IgG) conjugated to
AlexaFluor 647 (4 μg/mL, Invitrogen), donkey α-mouse IgG conju-
gated to AlexaFluor 647 (4 μg/mL, Invitrogen), and donkeyα-goat IgG
conjugated to AlexaFluor 647 (4 μg/mL, Invitrogen). Membranes
were then scanned using an FLA-5000 (FujiFilm), and samples
were normalized to total M1 and M2 expression relative to wild-
type protein. Structural proteins and oligomeric forms of M2 are
indicated.
Flow cytometry
Cells were removed from the tissue culture plates with trypsin
treatment. The trypsin was inactivated with serum containing media
and cells were washed once with PBS and incubated on ice for 30 min,
in the presence of blocking buffer (PBS supplemented with 0.5% BSA
and 3% normal goat serum (NGS, Sigma)). Cells were then incubated
for 1 h on ice with an antibody that recognizes the M2 ectodomain
(14C2MAb, 1:1000 dilution), washed three times with PBS, incubated
with goat α-mouse IgG conjugated to AlexaFluor 488 (4 μg/mL,
Invitrogen) for 1 h on ice, and washed three times with PBS. Cells
were then ﬁxed with 1% formaldehyde (Fisher Scientiﬁc) in PBS for
15 min at room temperature. The cells were analyzed on a
FACSCalibur (Beckton Dickinson) and quantiﬁed using FlowJo
software (Tree Star). All antibody dilutions were made in blocking
buffer.
Microscopy
The cells were treated as for ﬂow cytometry except antibodies
were goat α-H3 sera raised against A/Aichi/2/68 (1:500 dilution, V-
314-591-157; National Institute of Allergy and Infectious Diseases)
and donkey α-goat IgG conjugated to AlexaFluor 555 (4 μg/mL,
Invitrogen). After incubation with antibodies, the cells were ﬁxed
with 2% paraformaldehyde (Sigma) in PBS for 15 min at room
temperature, washed twice with PBS, then mounted on slides using
ProLong Gold anti-fade (Invitrogen).
537S.M. Stewart et al. / Virology 405 (2010) 530–538Samples were imaged on a Nikon Eclipse 90i microscope. For
quantiﬁcation, 10 or 20 images of random ﬁelds of view were taken
with a 20× objective in two separate experiments. For each image, the
number of infected cells and cells with ﬁlaments were counted and
used to determine the percentage of infected cells expressing
ﬁlaments. Data from one representative experiment are shown. For
high magniﬁcation images, Z-sections were taken at 0.3-μm intervals
on a Leica 510 Meta LSM confocal microscope using a 100× oil-
immersion lens. Volocity 3D imaging software (Improvision) was
used to analyze and ﬂatten Z-sections.Transmission electron microscopy
MDCK cells were grown to conﬂuency in 3.5-cm dishes and
infected at an MOI of ~5 with either rUd or rUd M2 F54R. At 10 hpi,
cells were washed twice with PBS and ﬁxedwith 2 mL of fresh ﬁxative
(2% glutaraldehyde, 0.1 M cacodylate, 3% sucrose, and 3 mM CaCl2 in
PBS pH7.4) overnight at 4 °C. Cells were post-ﬁxed with 1% osmium
tetroxide reduced in potassium ferrocyanide for 1 h at 4 °C. After
ﬁxation, cells were stained en bloc with a 2% aqueous solution of
uranyl acetate and dehydrated in graded ethanol. Embedding was
done in Eponate 12 Resin (Ted Pella). Thin sections (70–90 nm) were
cut on a Reichert-Jung Ultracut E and placed on 200 mesh copper
grids. The sections were stained with uranyl acetate and lead citrate
and viewed on a Hitachi 7600 TEM with an AMT digital camera.Infection of BALB/c mice
Six- to 8-week-old female BALB/c mice (Charles River) were used
as described previously (Newby et al., 2007; Wu and Pekosz, 2008).
Mice were anesthetized and administered an intranasal inoculation of
103 or 105 TCID50 of rWSN, rWSNM2 R54F, or rWSNM2 delCRAC virus
diluted in 20 μL DMEM supplemented with 100 U/mL penicillin,
100 μg/mL streptomycin, and 4 μg/mL NAT. Animals were monitored
for 14 dpi for morbidity and mortality (Wu and Pekosz, 2008).
Changes in body mass are graphed as percent of starting mass.Infection of mTEC cultures
Mouse tracheal epithelial cells (mTECs) were harvested, isolated,
and differentiated as described previously (Ibricevic et al., 2006a;
Newby et al., 2007). Cultures were infected via the apical chamber
with 3300 TCID50 in 100 μL of media, ~0.01 MOI assuming all cells are
susceptible to infection. After 1 h, apical supernatants were removed
and replaced with fresh media. At the indicated hpi, apical and
basolateral supernatants were removed and replaced with fresh
media. Throughout the infection, infectious media without NAT were
used. Infectious virus titers were quantiﬁed at indicated times as
above. Standard error of the mean is graphed from infections done in
duplicate.Statistical analysis
Infectious virus production and body mass changes were analyzed
using mixed ANOVAs with time and virus as the independent
variables. Protein concentrations and differences in the percentage
of cells with ﬁlaments were calculated using t-tests. Mean day of
death was determined by log-rank test. Signiﬁcant interactions were
further evaluated using the Tukey method for pairwise multiple
comparisons. Statistically signiﬁcant differences of *pb0.05 or
**pb0.01 are indicated, and all analyses were done with Prism 4.0
(GraphPad Software Inc.).Acknowledgments
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